Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8821-8830 Newer>

Chemistry World April 29, 2014 Phillip Broadwith	Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
Chemistry World April 25, 2014 Phillip Broadwith	Generics triumph in anti-inflammatory patent battle Pfizer has settled a long-running patent dispute with generics heavyweights Teva and Actavis, which will allow them to produce generic versions of Pfizers non-steroidal anti-inflammatory drug Celebrex (celecoxib) in the US.
Chemistry World April 25, 2014 Andy Extance	$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.
Chemistry World April 24, 2014 Emma Stoye	European parliament backs new rules on legal highs New regulations that will make it easier to ban legal highs have been backed by the European parliament.
Chemistry World April 23, 2014 Phillip Broadwith	GSK corruption investigation widens Pharma giant GlaxoSmithKline has responded to allegations made by the BBC's Panorama program concerning improper conduct by GSK's sales staff in Poland.
HBS Working Knowledge April 21, 2014 Carmen Nobel	Bio-piracy: When Western Firms Usurp Eastern Medicine Raj Choudhury and Tarun Khanna examine the history of herbal patent applications, challenging a stereotype that characterizes Western firms as innovators and emerging markets as imitators.
Chemistry World April 11, 2014 Andy Extance	Missing safety risk emails draw $9bn Actos fine A US jury has fined Takeda and Eli Lilly $9 billion for causing a man's bladder cancer with their diabetes drug Actos (pioglitazone).
Pharmaceutical Executive April 10, 2014 Christini & Kaitin	Regional Trends in Bioinnovation Investment Can the Cambridge model be duplicated?
Pharmaceutical Executive April 10, 2014 Joanna Breitstein	HBA's Women of the Year 2014 The Healthcare Businesswomen's Association honored three female leaders this year. We take an in-depth look at each winner's background and career and what factors helped push them to the top of their game.
<Older 8821-8830 Newer> Return to current articles.